The present disclosure provides a system (108) and a method (300) for analyzing postures, angles and generating recommendations. The system (108) receives one or more inputs from a user (102). The system (108) recommends one or more exercise routines personalized to the user (102). The system (108) receives a request for analyzing one or more postures or angles performed by the user (102) during the one or more exercise routines for a predetermined period. The system (108) analyzes, via an artificial intelligence (AI) engine (214), the one or more postures or angles of the user for the predetermined period. The system (108) generates a recommendation based on the analyzed one or more postures, angles and the clinical profile of the user (102). The system (108) causes to display, the recommendation to the user (102) to enable the user (102) to modify the one or more postures as a corrective measure and improve the repetitions performed by the user (102).
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
A63B 24/00 - Electric or electronic controls for exercising apparatus of groups
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present invention relates to pharmaceutical formulations of antibodies and antigen-binding fragments against human CD20 and method for preparing the same. The disclosed formulations are free of sugar or sugar alcohol and stabilizes anti-CD20 antibody from lower to higher concentrations rendering it suitable for different modes of administration (subcutaneous/intravenous).
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to pharmaceutical formulations of antibodies and antigen-binding fragments against human CD20 and method for preparing the same. The disclosed formulation composition stabilizes anti-CD20 antibody from lower to higher concentrations rendering it suitable for different modes of administration (subcutaneous/intravenous).
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical and medicinal products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical and medicinal products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical and medicinal products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical and medicinal products.
The present application relates to a method of orally administering once daily tablet of minocycline to a subject in need thereof, wherein said tablet is substantially free of lactose. The present application also relates to processes for preparing said once daily tablet of minocycline that provides reduced stock keeping units with improved inventory by supplying multiple doses of minocycline in single tablet.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
The current invention discloses a method for obtaining a purified antibody composition. The method discloses the use of various chromatography steps in a particular order to obtain a purified composition of a therapeutic monoclonal antibody starting from a composition comprising the monoclonal antibody and one or more process and product related impurities. Further, the method also discloses the use of additional purification steps such as depth filtration, diafiltration, ultrafiltration and tangential flow filtration for obtaining the said purified antibody composition.
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to pharmaceutical formulations of antibodies and antigen-binding fragments against human programmed death receptor-1 (PD-1) or programmed death receptor Ligand 1 (PD-L1), and method for preparing the same. The disclosed formulations are free of sugar or sugar alcohol and stabilizes anti-PD1/anti-PD L1 antibody from lower to higher concentrations rendering it suitable for different modes of administration (subcutaneous/intravenous).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a cell culture process for producing a monoclonal antibody composition, the process comprising culturing the mammalian cells at a pH range of about 6.6 to about 7.5, performing a temperature shift from a first culture temperature to a second culture temperature, supplementation of galactose in the cell culture, thereby obtaining an antibody composition comprising galactosylated glycoform and/or G0F glycoform. Further, the cell culture process disclosed in the present invention obtains an antibody composition comprising galactosylated glycoform wherein the percentage of galactosylated glycoform decreases with the decrease in the difference between the first temperature and the second temperature.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
34.
Method To Control High Molecular Weight Aggregates In An Antibody Composition
The method disclosed in the current invention is used to purify an antibody from high molecular weight aggregates. The method discloses the use of anion exchange chromatography for the reduction of high molecular weight aggregates from the antibody composition, in particular, by contacting the antibody composition with the anion exchange resin at a specific pH and conductivity. The disclosed method eliminates the need for further chromatographic steps for the reduction of HMW aggregates.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present application provides an amorphous solid dispersion of Fruquintinib with one or more pharmaceutically acceptable carriers and processes for the preparation thereof. The present application specifically provides an amorphous solid dispersion of Fruquintinib with a pharmaceutically acceptable carrier, selected from a group of co-povidone, HPMC, HPMC-AS, Eudragit, HPC and mixtures thereof.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
The present application relates to novel crystalline forms of Danuglipron and processes for preparation thereof. Specifically, the present application relates to crystalline anhydrate and crystalline hydrate forms of Danuglipron. The present application further relates to crystalline Forms of Danuglipron selected from a group of DN1, DN2, DN3 and mixture thereof. The crystalline form of Danuglipron is used for the preparation of medicament for treating and preventing a disease, such as Type 2 Diabetes Mellitus, pre-diabetes, obesity, NASH, cardiovascular diseases etc., for which an agonist of GLP-1 receptor is indicated.
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
37.
A METHOD OF IMPROVING STABILITY OF IMMUNE CHECK POINT INHIBITORS
The present invention relates to pharmaceutical formulations of antibodies and antigen-binding fragments against human programmed death receptor-1 (PD-1)/programmed death receptor Ligand 1 (PD-L1), and method for preparing the same. The disclosed formulations stabilizes anti-PD1/anti-PD L1 antibody from lower to higher concentrations rendering it suitable for different modes of administration (subcutaneous/intravenous).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention discloses a stable buffer free formulation of anti-PD1/anti-PD-L1 antibody, comprising an anti-PD1 or an anti-PD-L1 antibody, water, mannitol and surfactant, and stabilized at a pH of about 5.0-about 6.0. The disclosed antibody formulation is a liquid formulation and can be lyophilized. Further, the said formulation is also suitable for different mode of administration such as subcutaneous/intravenous, for therapeutic use.
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
39.
METHOD FOR IDENTIFICATION AND QUANTIFICATION OF ANALYTES BY MASS SPECTROMETRY
The present invention discloses a method for precise identification and absolute quantitation of a wide array of analytes present in a sample at nanomolar to millimolar concentration ranges, by mass spectrometry in a single run. Specifically, present method can, in a single run, simultaneously identify and quantify upto 70 cell culture media components including amino acids, amino acid derivatives vitamins, organic acids and sugars or cellular metabolites using liquid chromatography mass spectrometry (LC-MS) coupled with triple quad detector (QqQ) using multiple reaction monitoring (MRM), present at the said concentration range, with substantial accuracy. The method is capable of distinguishing analytes with same or similar molecular mass, is also suitable across production scales and cell culture process types (eg. fed batch or continuous culture) and has immense industrial utility in guiding the cell culture feeding strategy by profiling analytes intermittently during the fermentation process.
The present invention relates to pharmaceutical formulations of antibodies and antigen-binding fragments against human programmed death receptor-1 (PD-1)/programmed death receptor Ligand 1 (PD-L1), and method for preparing the same. The disclosed formulations are free of chelators and stabilizes anti-PD1/anti-PD L1 antibody from lower to higher concentrations rendering it suitable for different modes of administration (subcutaneous/intravenous).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to immediate release pharmaceutical composition comprising amorphous solid dispersions of the protein kinase inhibitor, nilotinib or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising the same. More particularly, the present invention relates to improved pharmaceutical compositions of nilotinib, or a pharmaceutically acceptable salt thereof, that can be administered without regard to food 5 consumption and that can be administered at a significantly lower dose as compared to a commercially available immediate-release nilotinib formulation, while providing a comparable therapeutic effect. A method of preparation of the said compositions is also dislcosed.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 35/02 - Antineoplastic agents specific for leukemia
The present application relates to a oral composition comprising nutrients to address the nutrition deficiency in human subjects. Particularly the application relates to oral compositions comprising prebiotics and micronutrients. More particularly, the application relates to oral compositions comprising prebiotics, beta-glucan and micronutrients and the process of preparation for the same. The present application further relates to a nutritional composition in the form of gummies and process for preparation thereof.
The present invention relates to a mammalian cell culture process to modulate a pharmaceutical composition of a monoclonal antibody composition comprising galactosylated glycoform of the antibody, the process comprising 5 culturing the mammalian cells within a pH range of about 6.7 to about 7.4, performing a temperature shift from a first culture temperature to a second culture temperature, supplementing the cell culture with manganese or galactose, thereby obtaining an antibody composition comprising increased percentage of galactosylated glycoforms. Further, the cell culture process 10 disclosed in the present invention comprises culturing mammalian cells within a pH range of about 6.7 to about 7.4, performing a temperature shift from a first culture temperature to a second culture temperature, supplementing the cell culture with manganese or galactose, thereby obtaining a biosimilar monoclonal antibody composition comprising galactosylated glycoforms of the 15 biosimilar monoclonal antibody at a target/predetermined range as of that of the reference product.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; Medicinal preparations and substances; Medical preparations; Medicine; Medicines for human purposes; Pharmaceutical preparations; dietary supplements for human use; Pharmaceutical products.
54.
SOLID STATE FORMS OF PIRTOBRUTINIB AND PROCESS FOR THE PREPARATION OF INTERMEDIATE THEREOF
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Non-medicated cosmetics and toiletry preparations; Non-medicated dentifrices; Perfumery, essential oils; toothpaste; mouthwashes; Cosmetics; cosmetic creams; cosmetic preparations for skin care; herbal extracts for cosmetic purposes; lotions for cosmetic purposes; oils for cosmetic purposes; gels for cosmetic purposes, creams for cosmetic purposes, spray, shampoo, soaps and lotions for non-medical purposes; Non-medicated cosmetics preparations and substances containing cannabis. Pharmaceutical preparations for medical purposes, Medicines, Pharmaceutical and medicinal preparations for use in the treatment of allergies, analgesics, diabetes, asthma, osteoporosis and pain, nausea and vertigo; antibiotics; anti-hypertensives; diarrhea medication, anti-bacterial preparations, cardio-vascular preparations, dermatological preparations, and other pharmaceutical preparations for the treatment of diseases and medical conditions; nutritional supplements; haemostatics and sleep inducers, sanitary preparations and substances; food for babies; medical plasters and dressings; disinfectants; food supplements and dietary food supplements; medicated Gels, creams, spray, pain patch and lotions for medical purposes; food supplements; nutritional supplements containing CBD, Cannabis for medical purposes; marijuana for medical purposes; medicine; Medicinal preparations and substances containing cannabis and CBD; medicated skin care preparations; antiseptic body care preparations; herbal extracts for medical purposes; plant extracts for pharmaceutical purposes; medicinal oils; medicinal roots; medicinal tea; dietary supplements for human beings; lotions for pharmaceutical purposes; medicinal infusions; pharmaceutical preparations for skin care; pharmaceutical creams; body gels and nasal spray for pharmaceutical use; medicated gel to reduce inflammation and muscoskeletal pain; anti pain patch for swelling and pain relief of muscles and joints. Surgical instruments and apparatus; Medical apparatus and instruments; Dental apparatus and instruments; Orthopedic fixation devices; Scanners for medical diagnosis; Scanners for medical use; Artificial limbs; Eyes (Artificial -); Artificial teeth; Orthopedic implants; Orthopaedic supports; Orthopedic footwear; Orthopedic joint implants; Orthopaedic braces; Orthopedic belts; Suture materials; Devices for measuring blood sugar; Blood pressure measuring apparatus; Elastic bandages; Supportive Bandages. Medical assistance services; Pharmaceutical advice; Dentistry; Healthcare specialty services namely providing advanced medical, diagnostic or surgical services for human beings; Medical services involving the use of healthcare devices with associated software support, Telemedicine services based on app usage for health management; Providing health and medical information via a website; Providing medical and health information for use in the acquisition, storage, organizing, tracking, sharing, reporting and analysis of medical and physiological data via a website; providing medical data and information of patients via a website; medical consultations provided via online chat.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Cosmetics; hair lotions; soaps; shampoo; perfumery; essential oils; dentifrices; Deodorant for personal use. Pharmaceutical preparations for medical purposes, Medicines, Pharmaceutical and medicinal preparations for use in the treatment of allergies, analgesics, diabetes, asthma, osteoporosis and pain, nausea and vertigo; antibiotics; anti-hypertensives; diarrhea medication, anti-bacterial preparations, cardio-vascular preparations, dermatological preparations, and other pharmaceutical preparations for the treatment of diseases and medical conditions; nutritional supplements; haemostatics and sleep inducers, sanitary preparartions and substances; food for babies; medical plasters and dressings; disinfectants; food supplements and dietary food supplements. Surgical instruments and apparatus; Medical apparatus and instruments; Dental apparatus and instruments; Orthopedic fixation devices; Scanners for medical diagnosis; Scanners for medical use; Artificial limbs; Eyes (Artificial -); Artificial teeth; Orthopedic implants; Orthopaedic supports; Orthopedic footwear; Orthopedic joint implants; Orthopaedic braces; Orthopedic belts; Suture materials; Devices for measuring blood sugar; Blood pressure measuring apparatus. Medical assistance services; Pharmaceutical advice; Dentistry; Healthcare specialty services namely providing advanced medical, diagnostic or surgical services for human beings.
57.
Method To Purify An Antibody Composition Using Cation Exchange Chromatography
The method disclosed in the current invention is used to purify an antibody from process and product related impurities. The method discloses the use of cation exchange chromatography for the reduction of impurities such as high molecular weight aggregates, protein-A leachates and host cell proteins from an antibody composition. The disclosed method leads to a significant reduction of HMW aggregates and other process related impurities without compromising on the recovery of the protein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to an improved hair care shampoo composition which provides enhanced hair conditioning performance, anchorage, stimulation of hair growth, control of hair fall. The composition of present invention comprises Procapil, redensyl, one or more amino acid based conditioning agents, (iii) one or more foaming agents which is useful in the treatment of hair loss and improves hair anchorage. The compositions of the present invention are free of sulphate and parabens and also discloses the methods of preparing such compositions and use of such compositions in controlling the hair fall and improving the anchorage of the hair to scalp with good conditioning effect and promotes hair growth.
The present invention discloses a stable formulation of an α4β7 antibody, wherein the formulation comprises α4β7 antibody, amino acid, a mono carboxylic acid or dicarboxylic acid or dicarboxylic acid, and surfactant. The disclosed antibody formulations are liquid high concentration formulations that are also suitable for different mode of administration (subcutaneous/intravenous). The disclosed formulations exhibit stability under various accelerated stress conditions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
60.
PROCESS FOR PREPARATION OF NIRAPARIB TOSYLATE AND ITS INTERMEDIATES
The present application relates to a process for the preparation Niraparib of formula (II) or its pharmaceutically acceptable salts thereof. The present application also related to novel intermediates of Niraparib. Further, the present application also related to the application of such novel intermediates in the preparation of Niraparib of formula (II) and its tosylate salt of formula (I).
C07D 211/12 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
The present application relates to processes for the preparation of tirzepatide. The present application also relates to processes for the preparation of intermediate fragments of tirzepatide and their application in preparation of tirzepatide and pharmaceutically acceptable salts thereof. The present application also relates pharmaceutical compositions containing tirzepatide prepared by the process of the present invention.
The present invention discloses a cell culture method for producing a CTLA-4 fusion protein composition comprising a target % of monomer species of the fusion protein, wherein the cell culture method comprises addition of cysteine in the cell culture medium. The invention further discloses a cell culture process to produce CTLA-4 fusion protein composition with target % of monomer species involving a dual temperature shift with addition of cysteine. Also, the present invention provides a CTLA-4 fusion protein composition comprised of target % of monomer species and/or homodimer species of the CTLA-4 fusion protein.
The present invention relates to sustained release composition of Hydroxyzine or a pharmaceutically acceptable salt or a solvate thereof with less sedation. The present invention also relates sustained release compositions of Hydroxyzine hydrochloride comprising core matrix, barrier coating and film coating. The invention also relates to method of preparation of such compositions of Hydroxyzine or pharmaceutically acceptable salts or solvate thereof.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 9/22 - Sustained or differential release type
64.
STABLE AQUEOUS BUFFER FREE FORMULATION OF AN INTEGRIN ANTIBODY
The present invention discloses a buffer free formulation of high concentration α4β7 antibody, comprising α4β7 antibody, water, and surfactant, and stabilized at a pH of 6.0-6.5. The disclosed antibody formulations are liquid formulations and can be lyophilized. Further, the said formulations are also suitable for different mode of administration such as subcutaneous/intravenous, for therapeutic use.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention discloses an optimal lyophilization method to prepare a room-temperature-stable freeze-dried formulation of an anti-α4β7 antibody wherein the lyophilized anti-α4β7 antibody formulation obtained from the said method exhibits stability at room temperature for at least three months and reconstituted anti-α4β7 antibody formulation exhibits stability at room temperature at least for 24 hours.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
66.
STABLE THERAPEUTIC PROTEIN FORMULATION AND METHODS OF MAKING THE SAME
The present invention discloses a pharmaceutical formulation of antibody that binds to interleukin. The invention also discloses methods of making the same. The formulation composition comprises a weak organic acid and organic base buffer and pharmaceutically acceptable excipients. The said composition stabilizes the antibody by controlling aggregation, degradation, oxidation and formation of charge variants. The disclosed antibody formulations are liquid formulations that are also suitable for lyophilization.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
67.
COMPOSITIONS COMPRISING FUSION PROTEIN AND ANALYTICAL ATTRIBUTES THEREOF
The present invention discloses a therapeutic composition comprising fusion protein with reduced heterogeneity in the glycosylation profile of the protein and methods thereof. More particularly the invention provides the composition with reduced heterogeneity in the glycosylation profile. By reducing heterogeneity, the resultant preparation is expected to exhibit superior, consistent results in terms of safety, purity and potency. The invention is of particular importance as it can form the part of the critical quality attributes (CQA) that help in ensuring batch-to-batch consistency and predicted shelf-life of complex protein molecules.
The present invention discloses a method of cell culture for producing a fusion glycoprotein composition comprising a target glycosylation profile. More particularly, the invention provides a process to produce a glycoprotein composition from mammalian cell culture, wherein the composition comprises a target total sialylated and or di- and tri-sialylated N-glycan variant.
The present invention discloses a stable pharmaceutical formulation of an α4β7 antibody, wherein the formulation contains buffer, PEG, salt, amino acid and surfactant and wherein the formulation is devoid of sugar and/or sugar alcohols. The disclosed antibody formulations are liquid formulations, and are also suitable to be formulated as a lyophilized powder.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/19 - Particulate form, e.g. powders lyophilised
The present application relates to process for preparation of Mavacamten, preparative methods of various crystalline forms of Mavacamten and amorphous form of Mavacamten, its preparative method, and pharmaceutical compositions thereof. The present application also relates to solid dispersions of Mavacamten, their preparative methods and pharmaceutical compositions containing solid dispersions of Mavacamten.
The present invention provides an improved process for the preparation of Voclosporin, comprising oxidation of cyclosporin A acetate with potassium osmate and N-methyl morpholine N-oxide (NMMO) followed by sodium periodate and further conversion to Voclosporin. The present invention also covers crystallization of crude Voclosporin from acetone and heptane mixture.
The free thiol group present in free cysteines in recombinant therapeutic antibodies are reactive to process components and generates product variants during early stages of biosimilar development. Free thiol group present on the structural motifs, especially in the complementary determining regions (CDR), support maximal antigen binding capability. Product variants associated with these free thiol groups are detrimental for safety and efficacy of these therapeutic antibodies. Methods to identify and characterize various thiol variants an antibody composition is provided and an anti-IL-17A IgG1 composition having these thiol variants are described.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
73.
A PHARMACEUTICAL FORMULATION OF A THERAPEUTICANTIBODY AND PREPARATIONS THEREOF
The present invention relates to pharmaceutical formulations of anti-CD38 antibodies. In particular, the invention discloses a composition stabilizing the antibodies from its lower to higher concentration. The stable composition thus obtained can be formulated as intravenous and subcutaneous formulations with the desired antibody concentrations enabling therapeutic use. The prepared composition, additionally controls fragmentation of the antibody during storage.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Aspects of the present application relates to amorphous solid dispersions of evocalcet with polymer matrix, formic acid salt of evocalcet and process for the preparation of evocalcet.
C07C 211/30 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
75.
METHOD FOR SELECTIVE REDUCTION OF DISULFIDE BONDS IN AN IMMUNOGLOBULIN
The present invention discloses a method for the selective reduction of disulfide bonds in an immunoglobulin composition. More specifically, the method disclosed in the current invention is capable of selectively reducing the inter-chain disulfide bond between the light and heavy chain of an immunoglobulin without the use of commonly used chemicals such as DTT, DTE, and β- mercaptoethanol. The method is advantageous over the existing methods as it eliminates the need of an additional purification step to remove the chemicals used for reduction, i.e., DTT, DTE, etc. before subjecting the immunoglobulin sample for further analyses such as LC-MS..
The present invention provides 6-substituted pyridazine compounds of formula (I)
The present invention provides 6-substituted pyridazine compounds of formula (I)
The present invention provides 6-substituted pyridazine compounds of formula (I)
which are therapeutically useful as SMARCA2 and/or SMARCA4 degraders. These compounds are useful in the treatment and/or delaying progression of diseases or disorders dependent upon SMARCA2 and/or SMARCA4 in a subject. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer or a tautomer or a prodrug thereof.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention relates to liquid injectable compositions of trilaciclib or pharmaceutical acceptable salts, hydrates, solvates, polymorphs, and mixtures thereof. More particularly, the present invention relates to liquid injectable compositions which are either ready-to-dilute or ready-to-use or reconstituted from lyophilized forms of trilaciclib and further comprise of aqueous solvents or non-aqueous solvents of mixtures thereof.
The present application relates to process for the preparation of Tucatinib. The present application also relates to the process for the preparation of Tucatinib intermediates. The present application also provides a process for the preparation of amorphous tucatinib. The present application also provides tucatinib triflate salt characterized by PXRD peaks.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention discloses a method for the purification of Fc-fusion proteins from the contaminants. In particular, the disclosed method describes a process for the purification of Fc-fusion proteins using a specific order of chromatographic steps. The specific order of chromatography steps as disclosed results in reducing contaminants such as high-molecular weight aggregates and sialylated isoforms and obtaining a purified Fc-fusion protein composition.
The present invention discloses a high concentration formulation of an α4β7antibody, comprising α4β7antibody, amino acid(s), salt and surfactant, wherein the free amino acid(s) are hydrophobic amino acids and/or basic amino acid (s). The disclosed antibody formulations are liquid formulations that are also suitable for different mode of administration (subcutaneous/intravenous) and exhibits stability under various accelerated conditions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
The present application relates to a process for the preparation of semaglutide. The present application also relates to a recombinant process for the preparation of semapeptide. The present invention is related to a process for producing semapeptide, the process comprising the steps of, a) culturing a host cell comprising a nucleotide sequence encoding of Formula (II) under suitable conditions for expression, wherein, insoluble tag is a nucleotide sequence of Alanine-Valine; b) recovering semapeptide, wherein semapeptide amino acid sequence is Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly.
The method disclosed in the current invention is used to purify an antibody from process and product related impurities. The method discloses the use of affinity chromatography, cation exchange chromatography and mixed-mode chromatography for the reduction of process and product-related impurities. More specifically, the method discloses the use of cation exchange chromatography for the reduction of impurities such as high molecular weight aggregates and charge variants from an antibody composition.
The present application relates to amorphous solid dispersions of Deucravacitinib, process for the preparation of amorphous solid dispersion of Deucravacitinib, process for the preparation crystalline form of Deucravacitinib and process for the preparation of stable premix of amorphous solid dispersion of Deucravacitinib together with at least one pharmaceutically acceptable polymer matrix and syloid.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present application relates to substantially pure Sitagliptin and its pharmaceutically acceptable salts, and more particularly a process for preparing substantially pure Sitagliptin and its pharmaceutically acceptable salts and pharmaceutical compositions thereof. The present application also describes pharmaceutical compositions comprising sitagliptin or a salt thereof having less than about 100 ppm of compound of formula VII and/or less than about 1 ppm of Nitrosamine impurity of the compound of formula VIII.
The present invention relates to method culturing of mammalian cells expressing recombinant proteins. The cell culture method of the present invention implements the N-1 seed stage and the N stage production phase in the same bioreactor. In particular the cell culture method of the present invention provides for consistency in product quailty and productivity upon scale up of the early stage cell culture methods.
The present specification relates to pharmaceutical composition comprising duloxetine, or pharmaceutically acceptable salts thereof, and capsaicin. The present specification more particulary relates to topical pharmaceutical composition comprising duloxetine, or pharmaceutically acceptable salts thereof, and capsaicin, for the treatment and/or management of neuropathic pain. Methods of preparing such compositions are also provided.
The present invention provides 5-cyclopropyl-1H-pyrazol-3-yl-amine derivatives of formula (I), which are therapeutically useful as selective CDK12/13 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or disorders associated with CDK12/13 in a mammal. The present invention also provides the preparation of the compounds and pharmaceutical compositions that have at least one of the 5-cyclopropyl-1H-pyrazol-3-yl-amine derivatives of formula (I) or a pharmaceutically acceptable salt, an N-oxide or a stereoisomer thereof.
The present invention provides 5-cyclopropyl-1H-pyrazol-3-yl-amine derivatives of formula (I), which are therapeutically useful as selective CDK12/13 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or disorders associated with CDK12/13 in a mammal. The present invention also provides the preparation of the compounds and pharmaceutical compositions that have at least one of the 5-cyclopropyl-1H-pyrazol-3-yl-amine derivatives of formula (I) or a pharmaceutically acceptable salt, an N-oxide or a stereoisomer thereof.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to oral solid pharmaceutical dosage forms comprising proton pump inhibitor, as single active drug. The present specification specifically relates to orally disintegrating tablets that readily disintegrates in the mouth, releasing enteric coated drug pellets or units, comprising a proton pump inhibitor, Rabeprazole or a pharmaceutically acceptable salt thereof. The specification also relates to modified release oral dosage forms, which comprise of a core and a combination of a release modifying layers that together achieve beneficial release properties, suitable for once daily administration. The application also relates to processes for preparing the dosage forms as well as their use in the treatment of gastrointestinal diseases.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
The present application relates to a process for preparation of relugolix or its pharmaceutically acceptable salts thereof. The present application also relates to the process for preparation of Relugolix crystalline form R1.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61P 5/00 - Drugs for disorders of the endocrine system
C07D 333/38 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
92.
HERBAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LIVER DISORDERS
The present invention relates to a pharmaceutical composition comprising combination of herbal powder and standardised solvent extract(s) of the herbal mixture. More particularly, the present invention relates to pharmaceutical composition comprising combination of herbal powder and standardised solvent extract(s) of the herbal mixture useful for the treatment of liver and kidney disorders. The invention also provides the process for the preparation of such compositions.
The present disclosure relates to methods of treating cancer using a therapeutically effective amount of an aminopyrazole derivative, as a CDK7 inhibitor, as a single agent therapy or in combination with one or more additional therapeutic agents. In particular, the cancer is selected from epithelial ovarian cancer, triple negative breast cancer, hormone receptor-positive breast cancer, and metastatic castration resistant prostate cancer.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
